

Procter & Gamble Hygiene and Health Care Limited CIN: L24239MH1964PLC012971 Registered Office: P&G Plaza Cardinal Gracias Road, Chakala Andheri (E), Mumbai 400 099 Tel: (91-22) 2826 6000 Fax: (91-22) 2826 7337 Website: in.pg.com

November 10, 2020

To, The Corporate Relations Department The BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001 **Ref:- Scrip Code:- 500459** To, The Listing Department The National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400051 **Ref:- Scrip Code:- PGHH**

Dear Sir / Madam,

Sub:- Unaudited Financial Results for the quarter ended September 30, 2020

We are pleased to inform you that at a meeting of the Board of Directors of the Company held today, the Unaudited Financial Results for the quarter ended September 30, 2020 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended September 30, 2020;
- b. Press Release; and
- c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended September 30, 2020 furnished by Statutory Auditors of the Company.

Kindly take the same on record. Thanking you.

Yours faithfully,

For Procter & Gamble Hygiene and Health Care Limited

Flavia Machado

Flavia Machado Company Secretary

P&G

Procter & Gamble Hygiene and Health Care Limited CIN : L24239MH1964PLC012971 Registered Office: P&G Plaza Cardinal Gracias Road, Chakala Andheri (E), Mumbai 400 099 (91 – 22) 2826 6000 phone (91 – 22) 2826 7337 fax Website: in.pg.com

	STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUA	RTER ENDED 30th SE	PTEMBER 2020		(Rs. in Lakh
		(1)	(2)	(3)	(4)
			Preceding	Corresponding	Previous
	Particulars	Three Months	Three Months	Three Months	Year
		Ended	Ended	Ended	Ended
		30th Sept 2020	30th June 2020	30th Sept 2019	30th June 2020
			(Audited)		
			Refer Note 3		
		(Unaudited)	below	(Unaudited)	(Audited)
		4 00 045	00.450	05 044	0.00.400
1	Revenue from operations	1 00 945	63 453	85 214	3 00 199
2	Other income	956	955	1 102	4 411
3	Total income (1+2)	1 01 901	64 408	86 316	3 04 610
4	Expenses				
a)	Cost of raw and packing materials consumed	32 896	23 387	33 050	1 06 217
c)	Purchases of stock-in-trade (Traded goods)	800	588	1 127	5 240
c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	622	(422)	(862)	(782)
j)	Employee benefits expense	6 148	3 810	4 207	17 329
e)	Finance costs	36	104	36	607
f)	Depreciation expense	1 180	1 320	1 145	4 788
g)	Impairment losses (Refer Note 2)				1 388
h)	Advertising & sales promotion expenses	9 020	4 109	10 446	32 830
i)	Other expenses	17 629	20 950	19 029	77 606
.,	Total expenses	68 331	53 846	68 178	2 45 223
	·				
5	Profit before tax (3-4)	33 570	10 562	18 138	59 387
6	Tax expense				
a)	Current tax	8 810	2 829	4 305	15 670
b)	Deferred tax	(254)	812	149	775
c)	Prior year tax adjustments	(372)			(366)
		8 184	3 641	4 454	16 079
7	Profit for the period (5-6)	25 386	6 921	13 684	43 308
8	Other comprehensive income				
	Items that will not be reclassified to profit or loss:				
	Re- measurement of the defined benefit plans	(57)	(233)	(257)	(226)
	Income tax effect on above	14	59	65	57
	Total other comprehensive income for the period	(43)	(174)	(192)	(169)
9	Total comprehensive income for the period (7+8)	25 343	6 747	13 492	43 139
, 10	Paid-up equity share capital (Face Value ` 10 per equity share)	3 246	3 246	3 246	3 246
11	Other Equity	5 240	5 240	5 240	1 12 540
12	Earnings per Share (Face value of ` 10 per equity share) (not annualised) :				1 12 340
12 a)	Basic	78.21	21.32	42.16	133.42
a) 5)	Diluted	78.21	21.32	42.16	133.42
		78.21	21.32	42.10	133.42
ье	e accompanying notes to the financial results				

Notes:

1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 10th November, 2020 and have been subjected to a limited review by the Statutory Auditors of the Company.

2 Certain Property, Plant & Equipment that had been classified as "Held for Sale" was impaired and recorded at its then fair value in the year ended June 30, 2018. In the previous year, during the quarter ended March 31, 2020, the Company had, based on certain quotes obtained, reassessed the fair value of these assets and a further impairment loss amounting to Rs. 1,388 lakh was recognized in the Statement of Profit and Loss. The company intends to dispose off the said PPE and is actively engaged in identifying a prospective buyer. These assets continue to be classified as held for sale as at September 30, 2020.

3 The figures for the preceding three months ended June 30, 2020 are the balancing figures between the audited figures in respect of the full financial year ended June 30, 2020 and the year to date figures upto the third quarter of that financial year.

4 The Company has identified Health and Hygiene Products as its single primary reportable segment in accordance with the requirements of Ind AS 108 - Operating Segments. Accordingly, no separate segment information has been provided.

5 As a result of the nationwide lockdown imposed by the Government of India in view of the Covid-19 pandemic, the operations of the Company were temporarily disrupted at its manufacturing, warehouse and distribution locations from second half of March 2020. The operations have gradually resumed in a phased manner in line with the Government directives issued from time to time. The Company's Management has evaluated the impact of this pandemic on its business operations and financial position and based on such review, there is no significant impact on the Company's assets, capital and financial resources, profitability parameters or liquidity positions as at September 30, 2020. The Management does not envisage any impact on the going concern assumption in the foreseeable future. However, the impact assessment of COVID-19 will be a continuing process given the uncertainties associated with its nature and duration.

6 The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.

7 Previous period figures have been regrouped / reclassified wherever necessary.

For and on behalf of the Board of Directors of Procter & Gamble Hygiene and Health Care Limited

MADHUS UDAN GOPALAN GOPALAN Date: 2020.11.10 Madhusudan Gopalan Managing Director



Procter & Gamble Hygiene and Health Care Limited CIN: L24239MH1964PLC012971 Registered Office: P&G Plaza Cardinal Gracias Road, Chakala Andheri (E), Mumbai - 400099 Tel: (91-22) 2826 6000 Fax: (91-22) 2826 7337 Website: in.pg.com

Procter & Gamble Hygiene and Health Care Ltd. announces first quarter results

Sales up 18% and PAT up 86% for the quarter ended September 30, 2020

Mumbai, November 10, 2020: Procter & Gamble Hygiene and Health Care Ltd. announced today its financial results for the quarter ended September 30, 2020. For the quarter ended September 30, 2020, the company delivered sales of ₹1009 crores, up 18% vs year ago behind the strength of our trusted brand portfolio, strong retail execution, and market recovery. Profit After Tax (PAT) for the quarter was ₹254 crores, up 86% vs year ago behind focus on productivity, one-time hurt in the corresponding quarter of the previous year, and a one-time help in the current quarter. In management's estimate, the Profit excluding the one-time items, for the quarter was up ~25%. The feminine care business delivered double-digit sales growth in the quarter while sales for the healthcare business grew in high single digits.

Madhusudan Gopalan, Managing Director, Procter & Gamble Hygiene and Health Care Ltd. said, "We delivered strong top and bottom-line results in a challenging market environment. With the easing of the lockdown, we are witnessing gradual market recovery in the health and hygiene categories. Our production and service are now back to pre-COVID levels. In the near term, we will continue to prioritize the health and safety of our employees, maximize the availability of our products, which play an essential role in meeting the daily health and hygiene needs of consumers across the country, and support our communities." He further added, "In the long term, we will continue to stay focused on our strategy of driving superiority, improving productivity, and strengthening our organization and culture to deliver balanced growth."

As part of the company's COVID-19 relief program 'P&G Suraksha India', the company has supported the government and relief organizations with more than 22 lakh Whisper sanitary pads for female frontline workers and women and girls in underprivileged communities. The company's healthcare brand Vicks[®] has donated more than 33,000 protective hygiene and ration kits to the elderly people in need.

About Procter & Gamble Hygiene and Health Care Ltd.

Procter & Gamble Hygiene and Health Care Ltd. (PGHHCL) is one of India's fastest growing FMCG companies that has in its portfolio WHISPER – India's leading Feminine Hygiene brand, and VICKS – India's No. 1 Health Care brand and Old Spice. The company has carved a reputation for delivering high quality, value-added products to meet the needs of consumers. PGHHCL is committed to making every day in the lives of Indian consumers better through the quality of its products and the sincerity of its service. Please visit in.pg.com for the latest news.

For details contact: Madison Public Relations: Malika Bhavnani +91 9820496099; malika.bhavnani@madisonpr.in

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

REVIEW REPORT TO THE BOARD OF DIRECTORS PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED

- 1. We have reviewed the accompanying Statement of Unaudited Financial Results of *PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED* ("the Company") for the quarter ended September 30, 2020, together with the notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, (initialed by us for identification). This Statement which is the responsibility of the Company's Management has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 10, 2020, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KALYANIWALLA & MISTRY LLP CHARTERED ACCOUNTANTS

Firm Reg. No.: 104607W / W100166

Roshni Rayomand Marfatia

Roshni R. Marfatia PARTNER M. No.: 106548 UDIN: 20106548AAAAFT6384

Mumbai, November 10, 2020.

P&G

Procter & Gamble Hygiene and Health Care Limited CIN : L24239MH1964PLC012971 Registered Office: P&G Plaza Cardinal Gracias Road, Chakala Andheri (E), Mumbai 400 099 (91 – 22) 2826 6000 phone (91 – 22) 2826 7337 fax Website: in.pg.com

	STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUAR	TER ENDED 30th SE	PTEMBER 2020		(` in Lakhs)
		(1)	(2)	(3)	(4)
			Preceding	Corresponding	Previous
	Particulars	Three Months	Three Months	Three Months	Year
		Ended	Ended	Ended	Ended
		30th Sept 2020	30th June 2020	30th Sept 2019	30th June 2020
			(Audited)		
			Refer Note 3		
		(Unaudited)	below	(Unaudited)	(Audited)
1	Revenue from operations	1 00 945	63 453	85 214	3 00 199
2	Other income	956	955	1 102	4 411
3	Total income (1+2)	1 01 901	64 408	86 316	3 04 610
Ŭ			04 400		0 04 010
4	Expenses				
a)	Cost of raw and packing materials consumed	32 896	23 387	33 050	1 06 217
b)	Purchases of stock-in-trade (Traded goods)	800	588	1 127	5 240
c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	622	(422)	(862)	(782)
d)	Employee benefits expense	6 148	3 810	4 207	17 329
e)	Finance costs	36	104	36	607
f)	Depreciation expense	1 180	1 320	1 145	4 788
g)	Impairment losses (Refer Note 2)				1 388
h)	Advertising & sales promotion expenses	9 020	4 109	10 446	32 830
i)	Other expenses	17 629	20 950	19 029	77 606
	Total expenses	68 331	53 846	68 178	2 45 223
5	Dur Et h - form ((33 570	10 562	18 138	50 007
5 6	Profit before tax (3-4)	33 570	10 562	18 138	59 387
	Tax expense Current tax	0.040	0.000	4 205	45.070
a)		8 810	2 829	4 305	15 670
b)	Deferred tax	(254)	812	149	775
c)	Prior year tax adjustments	(372)			(366)
_		8 184	3 641	4 454	16 079
7	Profit for the period (5-6)	25 386	6 921	13 684	43 308
8	Other comprehensive income				
	Items that will not be reclassified to profit or loss:				
	Re- measurement of the defined benefit plans	(57)	(233)	(257)	(226)
	Income tax effect on above	14	59	65	57
	Total other comprehensive income for the period	(43)	(174)	(192)	(169)
9	Total comprehensive income for the period (7+8)	25 343	6 747	13 492	43 139
10	Paid-up equity share capital (Face Value ` 10 per equity share)	3 246	3 246	3 246	3 246
11	Other Equity				1 12 540
12	Earnings per Share (Face value of ` 10 per equity share) (not annualised) :				
a)	Basic	78.21	21.32	42.16	133.42
b)	Diluted	78.21	21.32	42.16	133.42
Sor	accompanying notes to the financial results				

Notes:

1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 10th November, 2020 and have been subjected to a limited review by the Statutory Auditors of the Company.

2 Certain Property, Plant & Equipment that had been classified as "Held for Sale" was impaired and recorded at its then fair value in the year ended June 30, 2018. In the previous year, during the quarter ended March 31, 2020, the Company had, based on certain quotes obtained, reassessed the fair value of these assets and a further impairment loss amounting to Rs. 1,388 lakh was recognized in the Statement of Profit and Loss. The company intends to dispose off the said PPE and is actively engaged in identifying a prospective buyer. These assets continue to be classified as held for sale as at September 30, 2020.

3 The figures for the preceding three months ended June 30, 2020 are the balancing figures between the audited figures in respect of the full financial year ended June 30, 2020 and the year to date figures upto the third quarter of that financial year.

4 The Company has identified Health and Hygiene Products as its single primary reportable segment in accordance with the requirements of Ind AS 108 - Operating Segments. Accordingly, no separate segment information has been provided.

5 As a result of the nationwide lockdown imposed by the Government of India in view of the Covid-19 pandemic, the operations of the Company were temporarily disrupted at its manufacturing, warehouse and distribution locations from second half of March 2020. The operations have gradually resumed in a phased manner in line with the Government directives issued from time to time. The Company's Management has evaluated the impact of this pandemic on its business operations and financial position and based on such review, there is no significant impact on the Company's assets, capital and financial resources, profitability parameters or liquidity positions as at September 30, 2020. The Management does not envisage any impact on the going concern assumption in the foreseeable future. However, the impact assessment of COVID-19 will be a continuing process given the uncertainties associated with its nature and duration.

6 The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.

7 Previous period figures have been regrouped / reclassified wherever necessary.

For and on behalf of the Board of Directors of Procter & Gamble Hygiene and Health Care Limited

MADHUS UDAN GOPALAN GOPALAN Date: 2020.11.10 Madhusudan Gopalan Managing Director